News – Page 1132 – Endpoints News

Confident he’ll be exonerated on fraud charges, Martin Shkreli is working on another attempt to “shock and awe”

9 years ago

SV debuts a new, $400M fund with a big focus on biotech startups

9 years ago

Megadeals keep investments up in lifesci’s Q1, but the tempo continues to slow for biotech

9 years ago

Neurocrine bags an FDA OK for tardive dyskinesia, trumping Teva as it preps first commercial launch

9 years ago

Jeremy Levin spotlights a trendy new way to build a pipeline with his $86M IPO for Ovid

9 years ago

David Meeker starts the next chapter of his long biotech career as chairman of the board

9 years ago

Nine blockbuster drugs to watch are making their debut, aiming at a $16B prize in 2021

9 years ago

PureTech launches an I/O startup inspired by NYU’s George Miller; SV adopts a new name

9 years ago

A serial biotech startup team is back in business, armed with $40M and a focus on NASH

9 years ago

The FDA is getting its hands on a ‘human emulation system,’ and Emulate hopes they never let go

9 years ago

Frequency Therapeutics gets a $32M startup round to help fine tune its hearing loss drug R&D

9 years ago

Good salary, nice bonus — but why did biotech mogul David Hung gamble on Axovant?

9 years ago

The FDA is keeping its partial hold on Repros’ Proellex

9 years ago

Private equity groups bag Stada in $5.6B buyout; Jefferies sees deteriorating prospects for AstraZeneca

9 years ago

The master dealmaker is back: David Hung takes the helm at Vivek Ramaswamy's Axovant

9 years ago

OncoMed shares crushed as Celgene-partnered lead drug flops and Bayer takes a pass on options

9 years ago

Geron survives, for now, but the jury at J&J is still out on the future of imetelstat

9 years ago

Roche’s Alecensa trumps Pfizer’s Xalkori in frontline ALK+ lung cancer

9 years ago

In the hunt for a $100M IPO, Biohaven polishes up discards from Bristol-Myers, AstraZeneca

9 years ago

J&J inks a $1.15B discovery deal with PeptiDream; Medivir plots PhIII HDAC program

9 years ago

Takeda continues global R&D reboot with a new joint venture with PRA

9 years ago

FDA nixes Merck’s shot at getting Januvia cardio safety data onto the label

9 years ago

Scott Gottlieb gave a savvy review of what we can expect at the FDA; When times got rough, a biotech CEO demonstrated ...

9 years ago

Candid Truths From A Biotech IPO

9 years ago

First page Previous page 1129 1130 113111321133 1134 1135 Next page Last page